Vladimir Hanes of Amgen's 2015 Presentation

Amgen’s meaningful biosimilar development programs

We were excited to have Vladimir Hanes, Medical Director of Oncology/Biosimilars at Amgen, share his expertise on the structure, function, and the science of biosimilarity in designing meaningful biosimilar development programs at last year’s World Biosimilar Congress USA. Download his presentation now > You can now download Vladimir’s presentation to find out more about: FDA & EU definitions of biosimilars …

Could Antibodies Provide the Answer to Curing Ebola?

Newly discovered antibody drugs such as ZMAPP could provide a solution to the Ebola epidemic that’s sweeping across the globe. We have known about the capacity of antibodies for modulating the immune system for decades, and there are already hundreds of antibody-based drugs that are used to effectively fight various illnesses such as cancer and autoimmune diseases. ZMAPP has been shown …

Download: Payer Engagement and Preparing Information to Support Value Proposition

Demonstrate value and improve payer engagement with tips from Jorge Arellano, MSc, MPhil, Director Global Health Economics, Amgen. In his presentation, given at Evidence USA 2013, he discusses these topics and more. Download to learn: Evidence Generation: The Process Evidence Generation: Key Deliverables Payers input Understanding Your Payer(s) Download presentation Discover how pharma, payers and patients are utilizing real world …

How is the post monoclonal antibodies (mAb) world going to develop in the future of biologics?

  As the pharma industry moves into the future of biologics production what challenges will they be facing? The field of biologics is currently on the brink of a new era of high tech drugs. These new drugs have been engineered to be more efficacious than typical mAbs by having a more targeted structure (i.e. antibody drug conjugates). Recently Amgen …

Total Biopharma interviews Richard Marlus, Amgen's Executive Medical Director

Amgen’s Executive Medical Director, Richard Markus, talks Biosimilars

In the world of biosimilars, there is quite some activity occurring, from a significant number of products under development to regulatory approvals to watch out for. With this in mind, and in preparation for the World Biosimilar Congress 2014, we’ve taken some time to conduct interviews with key members of the speaker faculty who are influential professionals of the biosimilar …

Download: Audits and inspections since the new PV legislation – a personal reflection

Sue Rees, EU QPPV, Executive Director, Global Safety, Amgen gave a presentation at last year’s World Drug Safety Congress Europe entitled “Audits and inspections since the new PV legislation – a personal reflection”. Download the presentation to learn What has not changed? What has changed? How can you prepare for an inspection QPPV oversight Take home messages Download presentation For …

Download: Both an innovator and a biosimilar player – an innovator perspective on developing a global biosimilar strategy

Download this presentation here > The World Biosimilar Congress  brings together pharma, biotech, academia and regulators and the wider service provider community to discuss the latest R&D, process, production, regulation and to-market strategies for biosimilar medicines. At the 2013 event, delegates were fortunate enough to hear from Dr Mourad Farouk, Medical Director – International Development, Amgen, who delivered the presentation ‘Both an innovator and a biosimilar player – an …

Biosimilar bill passed by California Assembly

The biosimilar market is a rapidly-growing segment of the pharmaceutical industry, but the US is still in the early stages of developing biosimilar regulation. In recent months, several US states have been contemplating passing bills on biosimilar drug use, and the California Assembly is the latest to pass such a bill. The Californian legislation would require pharmacies to notify doctors …

4 Amgen Pipeline mAbs Included in Japanese Amgen-Astellas Alliance

Amgen and Astellas Pharma Inc have announced that they have entered into an alliance to help address the unmet needs of Japanese patients. The two companies say the alliance combines Amgen's pipeline candidates with Astellas' knowledge of the Japanese market. The first element of the alliance will focus on the co-development and co-commercialization in Japan of these five Amgen pipeline …

The Top 3 Companies Set to Dominate US Biosimilar Market

Biosimilars – products that are "highly similar" to an already-approved biological product – are on the rise in the US, although the country still lags behind other nations in the biosimilar space.  A new report from Thomson Reuters, ‘An Outlook on US Biosimilar Competition', has identified these three pharmaceutical companies as being among those that have the greatest potential to …